Component

Moringa dry leaf powder

Species, preparation, dose and limitations are retained on linked claims.

8 recorded relationships. Experimental role, claim status and evidence remain attached to each record.

Read recorded mechanisms Open recursive mind map

How nutrients influence it

Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.

How nutrients reach it in more than one step

Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.

Tracing routes…

What it does

Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.

Recorded relationships

What it acts on

  1. In twenty healthy volunteers, concurrent Moringa leaf powder lowered amodiaquine Cmax, while seven-day pretreatment increased desethylamodiaquine Cmax and AUC; desethylamodiaquine AUC rose 40.4% with concurrent dosing and 188% after pretreatment.

    Moringa dry leaf powder → Human amodiaquine and desethylamodiaquine pharmacokinetic exposure source_derived_draftungraded
    Experimental context and source evidence
    dose
    Single amodiaquine 10 mg/kg with concurrent 3 g Moringa or after 3 g/day for seven days
    duration
    Concurrent dose or seven-day pretreatment
    evidence_access
    Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
    evidence_scope
    literature_reviewed; model-specific source-derived curation
    experimental_model
    Twenty healthy adults in a three-period study
    limitations
    Pharmacokinetic changes may not translate directly to efficacy or toxicity; the open sequence and specific powder schedule limit generalization.
    nutrient_topic
    Moringa oleifera chapter; interacting nutrients, drugs, peptides and proteins retain their experimental settings. · Moringa oleifera
    organism
    Twenty healthy adults in a three-period study
    plain_language
    In twenty healthy volunteers, concurrent Moringa leaf powder lowered amodiaquine Cmax, while seven-day pretreatment increased desethylamodiaquine Cmax and AUC; desethylamodiaquine AUC rose 40.4% with concurrent dosing and 188% after pretreatment.
    primary_references
    Moringa oleifera leaf powder alters the pharmacokinetics of amodiaquine in healthy human volunteers. (2018). https://pubmed.ncbi.nlm.nih.gov/29920710/ DOI: 10.1111/jcpt.12725
    route
    Oral
    tissue
    Amodiaquine and desethylamodiaquine plasma pharmacokinetics

    Moringa oleifera: mechanism of action and interactions (2026-09-20) · lines 189–198

    Original AI-assisted source-specific curation with primary-study citations, model, exposure, route, duration, negative findings and limitations preserved. Not publisher full text. · supports · Twenty healthy adults in a three-period study · source_derived_draft · unverified_draft

    ## moringa-amodiaquine-pk-interaction In twenty healthy volunteers, concurrent Moringa leaf powder lowered amodiaquine Cmax, while seven-day pretreatment increased desethylamodiaquine Cmax and AUC; desethylamodiaquine AUC rose 40.4% with concurrent dosing and 188% after pretreatment. Model/species: Twenty healthy adults in a three-period study Tissue/system: Amodiaquine and desethylamodiaquine plasma pharmacokinetics Exposure: Single amodiaquine 10 mg/kg with concurrent 3 g Moringa or after 3 g/day for seven days Route: Oral Duration: Concurrent dose or seven-day pretreatment Limits: Pharmacokinetic changes may not translate directly to efficacy or toxicity; the open sequence and specific powder schedule limit generalization. Primary reference: Moringa oleifera leaf powder alters the pharmacokinetics of amodiaquine in healthy human volunteers. (2018). https://pubmed.ncbi.nlm.nih.gov/29920710/ DOI: 10.1111/jcpt.12725 Access: Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
    Complete structured claim and evidence

  2. The same escalating-dose study found no difference in six-hour plasma glucose exposure after 0, 1, 2 or 4 g Moringa leaf powder.

    Moringa dry leaf powder → Six-hour plasma glucose exposure after Moringa leaf powder source_derived_draftungraded
    Experimental context and source evidence
    dose
    Single 0, 1, 2 and 4 g leaf-powder doses
    duration
    Six hours
    evidence_access
    Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
    evidence_scope
    literature_reviewed; model-specific source-derived curation
    experimental_model
    Ten healthy adults
    limitations
    A null acute glucose response in healthy adults does not exclude effects during chronic use or in dysglycemia.
    nutrient_topic
    Moringa oleifera chapter; interacting nutrients, drugs, peptides and proteins retain their experimental settings. · Moringa oleifera
    organism
    Ten healthy adults
    plain_language
    The same escalating-dose study found no difference in six-hour plasma glucose exposure after 0, 1, 2 or 4 g Moringa leaf powder.
    primary_references
    Moringa Oleifera Leaf Increases Insulin Secretion after Single Dose Administration: A Preliminary Study in Healthy Subjects. (2016). https://pubmed.ncbi.nlm.nih.gov/27276742/
    route
    Oral
    tissue
    Plasma glucose concentration and AUC

    Moringa oleifera: mechanism of action and interactions (2026-09-20) · lines 123–132

    Original AI-assisted source-specific curation with primary-study citations, model, exposure, route, duration, negative findings and limitations preserved. Not publisher full text. · supports · Ten healthy adults · source_derived_draft · unverified_draft

    ## moringa-human-acute-glucose-null The same escalating-dose study found no difference in six-hour plasma glucose exposure after 0, 1, 2 or 4 g Moringa leaf powder. Model/species: Ten healthy adults Tissue/system: Plasma glucose concentration and AUC Exposure: Single 0, 1, 2 and 4 g leaf-powder doses Route: Oral Duration: Six hours Limits: A null acute glucose response in healthy adults does not exclude effects during chronic use or in dysglycemia. Primary reference: Moringa Oleifera Leaf Increases Insulin Secretion after Single Dose Administration: A Preliminary Study in Healthy Subjects. (2016). https://pubmed.ncbi.nlm.nih.gov/27276742/ Access: Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
    Complete structured claim and evidence

  3. In ten healthy adults, a single 4 g dose of Moringa leaf powder increased insulin AUC and the insulin-to-glucose AUC ratio by 74% compared with the no-Moringa baseline.

    Moringa dry leaf powder → Plasma insulin response to glucose challenge source_derived_draftungraded
    Experimental context and source evidence
    dose
    Single 0, 1, 2 and 4 g leaf-powder doses separated by two weeks
    duration
    Six hours
    evidence_access
    Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
    evidence_scope
    literature_reviewed; model-specific source-derived curation
    experimental_model
    Ten healthy adults in an escalating-dose crossover study
    limitations
    The small nonrandomized dose sequence in healthy volunteers does not establish chronic glycemic benefit or an effect in diabetes.
    nutrient_topic
    Moringa oleifera chapter; interacting nutrients, drugs, peptides and proteins retain their experimental settings. · Moringa oleifera
    organism
    Ten healthy adults in an escalating-dose crossover study
    plain_language
    In ten healthy adults, a single 4 g dose of Moringa leaf powder increased insulin AUC and the insulin-to-glucose AUC ratio by 74% compared with the no-Moringa baseline.
    primary_references
    Moringa Oleifera Leaf Increases Insulin Secretion after Single Dose Administration: A Preliminary Study in Healthy Subjects. (2016). https://pubmed.ncbi.nlm.nih.gov/27276742/
    route
    Oral
    tissue
    Plasma insulin and insulin/glucose AUC

    Moringa oleifera: mechanism of action and interactions (2026-09-20) · lines 112–121

    Original AI-assisted source-specific curation with primary-study citations, model, exposure, route, duration, negative findings and limitations preserved. Not publisher full text. · supports · Ten healthy adults in an escalating-dose crossover study · source_derived_draft · unverified_draft

    ## moringa-human-acute-insulin In ten healthy adults, a single 4 g dose of Moringa leaf powder increased insulin AUC and the insulin-to-glucose AUC ratio by 74% compared with the no-Moringa baseline. Model/species: Ten healthy adults in an escalating-dose crossover study Tissue/system: Plasma insulin and insulin/glucose AUC Exposure: Single 0, 1, 2 and 4 g leaf-powder doses separated by two weeks Route: Oral Duration: Six hours Limits: The small nonrandomized dose sequence in healthy volunteers does not establish chronic glycemic benefit or an effect in diabetes. Primary reference: Moringa Oleifera Leaf Increases Insulin Secretion after Single Dose Administration: A Preliminary Study in Healthy Subjects. (2016). https://pubmed.ncbi.nlm.nih.gov/27276742/ Access: Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
    Complete structured claim and evidence

  4. In a three-month cluster-randomized pilot, 20 g/day maternal Moringa leaf powder did not change human-milk vitamin A concentration or maternal and infant serum vitamin A status, although milk alpha-carotene rose modestly.

    Moringa dry leaf powder → Human-milk retinol concentration source_derived_draftungraded
    Experimental context and source evidence
    dose
    Corn porridge with or without 20 g/day leaf powder
    duration
    Three months
    evidence_access
    Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
    evidence_scope
    literature_reviewed; model-specific source-derived curation
    experimental_model
    Forty-four completing Kenyan breastfeeding mother-infant pairs
    limitations
    The small pilot had baseline alpha-carotene imbalance and was not powered to establish clinical infant benefit.
    nutrient_topic
    Moringa oleifera chapter; interacting nutrients, drugs, peptides and proteins retain their experimental settings. · Moringa oleifera
    organism
    Forty-four completing Kenyan breastfeeding mother-infant pairs
    plain_language
    In a three-month cluster-randomized pilot, 20 g/day maternal Moringa leaf powder did not change human-milk vitamin A concentration or maternal and infant serum vitamin A status, although milk alpha-carotene rose modestly.
    primary_references
    Impact of Maternal Moringa oleifera Leaf Supplementation on Milk and Serum Vitamin A and Carotenoid Concentrations in a Cohort of Breastfeeding Kenyan Women and Their Infants. (2024). https://pubmed.ncbi.nlm.nih.gov/39408390/ DOI: 10.3390/nu16193425
    route
    Maternal oral feeding
    tissue
    Milk retinol/carotenoids and serum retinol-binding protein

    Moringa oleifera: mechanism of action and interactions (2026-09-20) · lines 255–264

    Original AI-assisted source-specific curation with primary-study citations, model, exposure, route, duration, negative findings and limitations preserved. Not publisher full text. · supports · Forty-four completing Kenyan breastfeeding mother-infant pairs · source_derived_draft · unverified_draft

    ## moringa-maternal-milk-retinol-null In a three-month cluster-randomized pilot, 20 g/day maternal Moringa leaf powder did not change human-milk vitamin A concentration or maternal and infant serum vitamin A status, although milk alpha-carotene rose modestly. Model/species: Forty-four completing Kenyan breastfeeding mother-infant pairs Tissue/system: Milk retinol/carotenoids and serum retinol-binding protein Exposure: Corn porridge with or without 20 g/day leaf powder Route: Maternal oral feeding Duration: Three months Limits: The small pilot had baseline alpha-carotene imbalance and was not powered to establish clinical infant benefit. Primary reference: Impact of Maternal Moringa oleifera Leaf Supplementation on Milk and Serum Vitamin A and Carotenoid Concentrations in a Cohort of Breastfeeding Kenyan Women and Their Infants. (2024). https://pubmed.ncbi.nlm.nih.gov/39408390/ DOI: 10.3390/nu16193425 Access: Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
    Complete structured claim and evidence

  5. In eleven evaluable adults with HIV, 1.85 g/day Moringa leaf powder for 14 days did not significantly alter steady-state nevirapine AUC, Cmax or 12-hour concentration.

    Moringa dry leaf powder → Steady-state nevirapine AUC, Cmax and 12-hour concentration source_derived_draftungraded
    Experimental context and source evidence
    dose
    Nevirapine alone then with 1.85 g/day Moringa leaf powder
    duration
    14 days coadministration
    evidence_access
    Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
    evidence_scope
    literature_reviewed; model-specific source-derived curation
    experimental_model
    Adults with HIV receiving steady-state nevirapine
    limitations
    The small one-sequence study supports a null at this product and dose, not absence of interaction with every drug or preparation.
    nutrient_topic
    Moringa oleifera chapter; interacting nutrients, drugs, peptides and proteins retain their experimental settings. · Moringa oleifera
    organism
    Adults with HIV receiving steady-state nevirapine
    plain_language
    In eleven evaluable adults with HIV, 1.85 g/day Moringa leaf powder for 14 days did not significantly alter steady-state nevirapine AUC, Cmax or 12-hour concentration.
    primary_references
    Effect of Moringa oleifera Lam. leaf powder on the pharmacokinetics of nevirapine in HIV-infected adults: a one sequence cross-over study. (2017). https://pubmed.ncbi.nlm.nih.gov/28293270/ DOI: 10.1186/s12981-017-0140-4
    route
    Oral
    tissue
    Intensive 12-hour nevirapine pharmacokinetics

    Moringa oleifera: mechanism of action and interactions (2026-09-20) · lines 178–187

    Original AI-assisted source-specific curation with primary-study citations, model, exposure, route, duration, negative findings and limitations preserved. Not publisher full text. · supports · Adults with HIV receiving steady-state nevirapine · source_derived_draft · unverified_draft

    ## moringa-nevirapine-pk-null In eleven evaluable adults with HIV, 1.85 g/day Moringa leaf powder for 14 days did not significantly alter steady-state nevirapine AUC, Cmax or 12-hour concentration. Model/species: Adults with HIV receiving steady-state nevirapine Tissue/system: Intensive 12-hour nevirapine pharmacokinetics Exposure: Nevirapine alone then with 1.85 g/day Moringa leaf powder Route: Oral Duration: 14 days coadministration Limits: The small one-sequence study supports a null at this product and dose, not absence of interaction with every drug or preparation. Primary reference: Effect of Moringa oleifera Lam. leaf powder on the pharmacokinetics of nevirapine in HIV-infected adults: a one sequence cross-over study. (2017). https://pubmed.ncbi.nlm.nih.gov/28293270/ DOI: 10.1186/s12981-017-0140-4 Access: Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
    Complete structured claim and evidence

  6. An ancillary analysis of the same 12-week prediabetes trial found no between-group differences in inflammatory markers, serum lipids, plasma antioxidant capacity or blood pressure.

    Moringa dry leaf powder → Inflammatory, lipid, antioxidant-capacity and blood-pressure panel in prediabetes source_derived_draftungraded
    Experimental context and source evidence
    dose
    2.4 g/day dry leaf powder or placebo
    duration
    12 weeks
    evidence_access
    Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
    evidence_scope
    literature_reviewed; model-specific source-derived curation
    experimental_model
    Adults with prediabetes from the same randomized trial
    limitations
    This shares participants and intervention with PMID 35010932 and is one dataset, not independent replication.
    nutrient_topic
    Moringa oleifera chapter; interacting nutrients, drugs, peptides and proteins retain their experimental settings. · Moringa oleifera
    organism
    Adults with prediabetes from the same randomized trial
    plain_language
    An ancillary analysis of the same 12-week prediabetes trial found no between-group differences in inflammatory markers, serum lipids, plasma antioxidant capacity or blood pressure.
    primary_references
    Effects of Moringa oleifera Lam. Supplementation on Inflammatory and Cardiometabolic Markers in Subjects with Prediabetes. (2022). https://pubmed.ncbi.nlm.nih.gov/35565903/ DOI: 10.3390/nu14091937
    route
    Oral
    tissue
    Inflammatory and cardiometabolic biomarker panel

    Moringa oleifera: mechanism of action and interactions (2026-09-20) · lines 156–165

    Original AI-assisted source-specific curation with primary-study citations, model, exposure, route, duration, negative findings and limitations preserved. Not publisher full text. · supports · Adults with prediabetes from the same randomized trial · source_derived_draft · unverified_draft

    ## moringa-prediabetes-cardiometabolic-null An ancillary analysis of the same 12-week prediabetes trial found no between-group differences in inflammatory markers, serum lipids, plasma antioxidant capacity or blood pressure. Model/species: Adults with prediabetes from the same randomized trial Tissue/system: Inflammatory and cardiometabolic biomarker panel Exposure: 2.4 g/day dry leaf powder or placebo Route: Oral Duration: 12 weeks Limits: This shares participants and intervention with PMID 35010932 and is one dataset, not independent replication. Primary reference: Effects of Moringa oleifera Lam. Supplementation on Inflammatory and Cardiometabolic Markers in Subjects with Prediabetes. (2022). https://pubmed.ncbi.nlm.nih.gov/35565903/ DOI: 10.3390/nu14091937 Access: Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
    Complete structured claim and evidence

  7. In a 12-week double-blind trial in adults with prediabetes, 2.4 g/day Moringa dry leaf powder produced favorable fasting-glucose and HbA1c change scores relative to placebo.

    Moringa dry leaf powder → Fasting glucose and HbA1c trajectory in adults with prediabetes source_derived_draftungraded
    Experimental context and source evidence
    dose
    2.4 g/day dry leaf powder or placebo
    duration
    12 weeks
    evidence_access
    Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
    evidence_scope
    literature_reviewed; model-specific source-derived curation
    experimental_model
    Sixty-five randomized adults with prediabetes
    limitations
    The modest trial reports relative change trajectories and does not identify the active constituent or establish diabetes treatment efficacy.
    nutrient_topic
    Moringa oleifera chapter; interacting nutrients, drugs, peptides and proteins retain their experimental settings. · Moringa oleifera
    organism
    Sixty-five randomized adults with prediabetes
    plain_language
    In a 12-week double-blind trial in adults with prediabetes, 2.4 g/day Moringa dry leaf powder produced favorable fasting-glucose and HbA1c change scores relative to placebo.
    primary_references
    Moringa oleifera Leaf Supplementation as a Glycemic Control Strategy in Subjects with Prediabetes. (2021). https://pubmed.ncbi.nlm.nih.gov/35010932/ DOI: 10.3390/nu14010057
    route
    Oral
    tissue
    Fasting blood glucose and HbA1c

    Moringa oleifera: mechanism of action and interactions (2026-09-20) · lines 134–143

    Original AI-assisted source-specific curation with primary-study citations, model, exposure, route, duration, negative findings and limitations preserved. Not publisher full text. · supports · Sixty-five randomized adults with prediabetes · source_derived_draft · unverified_draft

    ## moringa-prediabetes-glycemia In a 12-week double-blind trial in adults with prediabetes, 2.4 g/day Moringa dry leaf powder produced favorable fasting-glucose and HbA1c change scores relative to placebo. Model/species: Sixty-five randomized adults with prediabetes Tissue/system: Fasting blood glucose and HbA1c Exposure: 2.4 g/day dry leaf powder or placebo Route: Oral Duration: 12 weeks Limits: The modest trial reports relative change trajectories and does not identify the active constituent or establish diabetes treatment efficacy. Primary reference: Moringa oleifera Leaf Supplementation as a Glycemic Control Strategy in Subjects with Prediabetes. (2021). https://pubmed.ncbi.nlm.nih.gov/35010932/ DOI: 10.3390/nu14010057 Access: Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
    Complete structured claim and evidence

  8. The same 12-week trial found no between-group differences in gut microbiota composition, hepatic or renal function markers, or the measured appetite-controlling hormones.

    Moringa dry leaf powder → Gut microbiota, hepatic/renal markers and appetite-hormone panel in prediabetes source_derived_draftungraded
    Experimental context and source evidence
    dose
    2.4 g/day dry leaf powder or placebo
    duration
    12 weeks
    evidence_access
    Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
    evidence_scope
    literature_reviewed; model-specific source-derived curation
    experimental_model
    Adults with prediabetes
    limitations
    The null applies to the measured endpoints, sample and exposure; it does not establish that every product is inert.
    nutrient_topic
    Moringa oleifera chapter; interacting nutrients, drugs, peptides and proteins retain their experimental settings. · Moringa oleifera
    organism
    Adults with prediabetes
    plain_language
    The same 12-week trial found no between-group differences in gut microbiota composition, hepatic or renal function markers, or the measured appetite-controlling hormones.
    primary_references
    Moringa oleifera Leaf Supplementation as a Glycemic Control Strategy in Subjects with Prediabetes. (2021). https://pubmed.ncbi.nlm.nih.gov/35010932/ DOI: 10.3390/nu14010057
    route
    Oral
    tissue
    Microbiota, organ-function markers and appetite hormones

    Moringa oleifera: mechanism of action and interactions (2026-09-20) · lines 145–154

    Original AI-assisted source-specific curation with primary-study citations, model, exposure, route, duration, negative findings and limitations preserved. Not publisher full text. · supports · Adults with prediabetes · source_derived_draft · unverified_draft

    ## moringa-prediabetes-metabolic-null The same 12-week trial found no between-group differences in gut microbiota composition, hepatic or renal function markers, or the measured appetite-controlling hormones. Model/species: Adults with prediabetes Tissue/system: Microbiota, organ-function markers and appetite hormones Exposure: 2.4 g/day dry leaf powder or placebo Route: Oral Duration: 12 weeks Limits: The null applies to the measured endpoints, sample and exposure; it does not establish that every product is inert. Primary reference: Moringa oleifera Leaf Supplementation as a Glycemic Control Strategy in Subjects with Prediabetes. (2021). https://pubmed.ncbi.nlm.nih.gov/35010932/ DOI: 10.3390/nu14010057 Access: Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
    Complete structured claim and evidence

In the sources

Preserved passages that mention this component, quoted exactly. Open one to read it in context.

    This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.

    Evidence, AI assistance and curation standards